2
Participants
Start Date
September 1, 2022
Primary Completion Date
April 11, 2024
Study Completion Date
April 11, 2024
Eltrombopag (Revolade®)
Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
standard therapy (without eltrombopag): HD-DXM
standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
University Children's Hospital Basel (UKBB), Basel
University Hospital Basel, Division of Hematology, Basel
Aarau Cantonal Hospital, Division of Hematology, Aarau
University Hospital Bern, Division of Hematology, Bern
Liestal Cantonal Hospital, Division of Hematology, Liestal
Lucerne Cantonal Hospital, Division of Hematology, Lucerne
Collaborators (1)
Stiftung zur Förderung medizinischer und biologischer Forschung
UNKNOWN
Novartis Pharmaceuticals
INDUSTRY
University of Erlangen-Nürnberg, Department of Biology
UNKNOWN
University Children's Hospital Basel
OTHER